Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Single-Arm R-CODOX-M/IVAC in High-Risk DLBCL or Burkitt Lymphoma
2005-003479-19Phase 2Completed
- Sponsor
- University College London
- Start
- Oct 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL), sponsored by University College London. Primary endpoint: Progression-free survival. Started Oct 2005; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Burkitt lymphoma (BL)
Beyond the preview
Go deeper on 2005-003479-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003479-19.